Utah Medical Products, Inc. — Q3 2014 Form 10-Q
Business context and period: UTMD manufactures and markets specialty medical devices. This unaudited report covers the quarter and nine months ended September 30, 2014; financial amounts below are in thousands of U.S. dollars except per-share data.
Financial performance
| Metric | Q3 2014 | Q3 2013 | 9M 2014 | 9M 2013 |
|---|---|---|---|---|
| Net sales | $10,717 | $10,032 | $31,035 | $30,408 |
| Gross profit | $6,196 | $5,949 | $18,595 | $18,279 |
| Operating income | $4,002 | $3,665 | $11,907 | $11,269 |
| Net income | $2,822 | $2,571 | $8,378 | $7,938 |
| Diluted EPS | $0.75 | $0.68 | $2.22 | $2.11 |
| Gross margin | 57.8% | 59.3% | 59.9% | 60.1% |
| Operating margin | 37.3% | 36.5% | 38.4% | 37.1% |
| Net margin | 26.3% | 25.6% | 27.0% | 26.1% |
Q3 sales increased 6.8% and net income 9.8% year over year; nine-month sales rose 2.1% and net income 5.5%. Filshie Clip System sales were a key growth driver. Gross margin declined, primarily because of product mix in Q3; nine-month margin also reflected higher U.S. employee medical costs. Operating expenses fell year over year, supporting higher operating margins.
Cash flow and liquidity: Nine-month operating cash flow was $10,858, versus $9,058 in 2013. Capital expenditures were $953, including $698 for a new Australian facility. Cash at September 30 was $18,248, up from $14,395 at year-end 2013; working capital was $19,421, versus $16,675. The company paid $1,874 in dividends and repurchased $1,017 of shares during the first nine months.
Debt and balance sheet: Total assets were $82,285 and total liabilities $18,063 at September 30. Bank debt totaled approximately $5,993 ($2,100 U.S. and $3,893 U.K.); $3,995 was classified as current and $1,998 as long term. Debt declined from $9,117 at year-end 2013, and all notes are scheduled to be repaid by March 2016. UTMD reported compliance with all loan covenants. Its total-liabilities-to-assets ratio was 22%, down from 25% at year-end.
Changes, outlook and risks
- Q3 international sales rose 8%; nine-month international sales rose 2%, despite a $784 decline in nine-month blood-pressure-monitoring sales to the China distributor. The delayed $396 China shipment was invoiced in Q3 after payment was received.
- Management said the company was on track after nine months to exceed its 2014 financial projections, but did not provide revised numerical guidance. Priorities include product development, operating performance, debt repayment, dividends, potential share repurchases and evaluating accretive acquisitions.
- Foreign exchange movements reduced reported equity and intangible-asset values and contributed to currency translation losses. UTMD does not use separate currency hedges. Q3 other comprehensive income included a $2,569 foreign-currency translation loss.
- Management cited medical-device excise taxes and healthcare reform, regulatory and premarket-approval burdens, group purchasing organizations, product-liability exposure, distributor dependence, competition and key-employee retention as risks. The filing reported no litigation believed likely to have a material financial outcome and no material subsequent events.
- A new revenue-recognition standard was issued in 2014; UTMD was assessing its impact, with adoption expected in 2017. Disclosure controls were considered effective, with no material change in internal controls reported during the quarter.
Important facts for investors to verify
- Whether fourth-quarter sales and earnings support management’s expectation of exceeding its 2014 projections; no updated numerical forecast was given.
- Whether Filshie Clip growth continues and whether China distributor sales recover, given the prior-year comparison and shipment timing.
- Whether gross-margin pressure from product mix and employee medical costs persists, and how foreign exchange affects reported results.
- Debt repayment progress, covenant compliance, and the sustainability of dividends and share repurchases alongside acquisition plans.
- Potential effects of medical-device regulation, healthcare reform and the excise tax on costs, competitiveness and demand.